Compare TKNO & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKNO | NYXH |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.1M | 152.8M |
| IPO Year | 2021 | 2021 |
| Metric | TKNO | NYXH |
|---|---|---|
| Price | $2.90 | $3.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.25 |
| AVG Volume (30 Days) | ★ 118.7K | 56.6K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,520,000.00 | N/A |
| Revenue This Year | $8.27 | $214.32 |
| Revenue Next Year | $13.13 | $124.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $1.91 | $2.76 |
| 52 Week High | $7.48 | $8.64 |
| Indicator | TKNO | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 45.83 |
| Support Level | $2.55 | $2.76 |
| Resistance Level | $3.22 | $3.32 |
| Average True Range (ATR) | 0.24 | 0.18 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 44.37 | 59.66 |
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.